Dr. Jose Penagaricano, MD

Dr. Penagaricano practices at Adventhealth Medical Group Surgical Specialists at Wesley Chapel - HOPD in Wesley Chapel, Florida.

Dr. Penagaricano's NPI, 1669556684, was assigned on October 25, 2006. Dr. Penagaricano graduated from Universidad Central del Caribe School of Medicine in 1992. Dr. Penagaricano's Arkansas license number on file is E-2813.

Dr. Penagaricano's primary practice is Adventhealth Medical Group Surgical Specialists at Wesley Chapel - HOPD, at 2590 Healing Way, Wesley Chapel, FL 33543.

Dr. Penagaricano's primary practice is Adventhealth Medical Group Surgical Specialists at Wesley Chapel - HOPD in Wesley Chapel, Florida. Dr. Penagaricano is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Penagaricano to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Penagaricano practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Penagaricano's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Penagaricano is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Penagaricano's licenses on file in 3 states: Arkansas, Florida and Pennsylvania.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, lung cancer radiation and lymphoma radiation among the conditions Dr. Penagaricano treats.

CMS data shows 1,518 Medicare services from Dr. Penagaricano across 11 procedure codes in 2024, for 228 Medicare patients. Medicare paid $103,627 for them.

CMS counts 228 Medicare patients who saw Dr. Penagaricano in 2024. The largest group is 65 to 74, with 118 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Penagaricano's median patient age at 69, with 37% women.

In 2024, Dr. Penagaricano wrote 81 Medicare Part D claims for 47 patients. 98% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $680 in total drug cost. In 2023, CMS named 71 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Penagaricano for performance year 2024, reported as part of a group. Dr. Penagaricano accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 37 papers to Dr. Penagaricano, published from 2009 to 2024. 2014 was the busiest year, with 3. The most frequent topics are Radiotherapy Planning, Computer-Assisted, Radiotherapy Dosage and Radiotherapy, Intensity-Modulated. Dr. Penagaricano has published most often in Med Phys. Dr. Penagaricano's most frequent co-authors are Matthew Emery Hardee, MD, PhD, Sanjay Maraboyina, MD and Daniel Eli Oliver, MD.

Dmand AI links Dr. Penagaricano to 3 clinical trials. Conditions studied include Radiation Injuries, Squamous Cell Carcinoma of Head and Neck and Xerostomia. University of Arkansas sponsors the most, 3.

CMS Open Payments shows 3 general payments to Dr. Penagaricano from 3 drug and device companies from 2017 to 2023. Food and beverage make up the largest share, 100% of the total. Augmenix, Inc. paid the most, $121.

Dr. Penagaricano graduated from Universidad Central del Caribe School of Medicine in 1992.

Dr. Penagaricano is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.